Vaccines as treatments for prostate cancer.

Nat Rev Urol · 2023 · PMC9987387 · PMID 36879114

Europe PMC DOI

hedged sentence

0.0520

closest p · 1.0× alpha

0.0520

boldest claim

The sentences

did not reach statistical significanceP = 0.052so close (0.05 < p ≤ 0.1)

Serum PSA decreases of >25% were detected in 6.8% of patients receiving sipuleucel-T; however, differences in the primary end point of TTP did not reach statistical significance ( P = 0.052) as patients receiving sipuleucel-T had a median TTP of 11.7 weeks (95% CI 9.1–16.6) compared with 10.0 weeks for patients receiving placebo (95% CI 8.7–13.1) 77 .

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.